Peripheral Neuropathy News and Research

RSS
Peripheral neuropathy describes damage to the peripheral nervous system, which transmits information from the brain and spinal cord to every other part of the body.

More than 100 types of peripheral neuropathy have been identified, each with its own characteristic set of symptoms, pattern of development, and prognosis. Impaired function and symptoms depend on the type of nerves -- motor, sensory, or autonomic -- that are damaged. Some people may experience temporary numbness, tingling, and pricking sensations, sensitivity to touch, or muscle weakness. Others may suffer more extreme symptoms, including burning pain (especially at night), muscle wasting, paralysis, or organ or gland dysfunction. Peripheral neuropathy may be either inherited or acquired. Causes of acquired peripheral neuropathy include physical injury (trauma) to a nerve, tumors, toxins, autoimmune responses, nutritional deficiencies, alcoholism, and vascular and metabolic disorders. Acquired peripheral neuropathies are caused by systemic disease, trauma from external agents, or infections or autoimmune disorders affecting nerve tissue. Inherited forms of peripheral neuropathy are caused by inborn mistakes in the genetic code or by new genetic mutations.
SLU investigator aims to reduce chemotherapy-induced peripheral neuropathy

SLU investigator aims to reduce chemotherapy-induced peripheral neuropathy

EpiCept seeks FDA Fast Track designation for AmiKet to treat CIPN

EpiCept seeks FDA Fast Track designation for AmiKet to treat CIPN

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

More efficient diagnostic tools are not always used for neuropathy patients

More efficient diagnostic tools are not always used for neuropathy patients

Researchers analyze tremendous cost of peripheral neuropathy diagnosis

Researchers analyze tremendous cost of peripheral neuropathy diagnosis

Takeda receives FDA approval for VELCADE sNDA to treat MM

Takeda receives FDA approval for VELCADE sNDA to treat MM

CMS assigns J-code for Eisai's Halaven Injection to treat breast cancer

CMS assigns J-code for Eisai's Halaven Injection to treat breast cancer

EpiCept receives FDA approval to commence AmiKet Phase III trial for CIPN

EpiCept receives FDA approval to commence AmiKet Phase III trial for CIPN

UCB initiates EXXELERATE study in rheumatoid arthritis

UCB initiates EXXELERATE study in rheumatoid arthritis

Three-drug combination therapy appears to be effective for newly diagnosed MM patients

Three-drug combination therapy appears to be effective for newly diagnosed MM patients

Onyx announces data from three carfilzomib studies on RRMM

Onyx announces data from three carfilzomib studies on RRMM

Acupuncture for chemotherapy-induced peripheral neuropathy

Acupuncture for chemotherapy-induced peripheral neuropathy

Clear link between erectile dysfunction and peripheral neuropathy

Clear link between erectile dysfunction and peripheral neuropathy

EpiCept reports net loss of $5.4 million for third quarter 2011

EpiCept reports net loss of $5.4 million for third quarter 2011

UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

Takeda receives FDA approval for VELCADE sNDA to treat MM

Takeda receives FDA approval for VELCADE sNDA to treat MM

UCB to present new data on Cimzia at ACG annual scientific meeting

UCB to present new data on Cimzia at ACG annual scientific meeting

J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

U-M researchers to study new approach in halting downward spiral of diabetes

U-M researchers to study new approach in halting downward spiral of diabetes

QUT program assists cancer survivors in self-managing their health, emotional concerns

QUT program assists cancer survivors in self-managing their health, emotional concerns

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.